leadf
logo-loader
RNS
viewVectura Group PLC

Vectura Group plc - Directors Declarations

RNS Number : 9513S
Vectura Group plc
23 March 2016
 

Vectura Group plc

 

Director disclosures

 

Chippenham, UK - 23 March 2016: 

As announced on 16 March 2016 (RNS Number: 2679S) (the "Announcement"), conditional on completion of the merger described in the Announcement, Vectura Group plc ("Vectura") intends that:

·      Andrew Derodra will be appointed as Chief Financial Officer of Vectura;

·      Frank Condella will be appointed as Vice Chairman of Vectura; and Thomas Werner will be appointed as a non-executive director of Vectura.

Further to the Announcement, Vectura confirms the following information in respect of the proposed future Board members pursuant to paragraph 9.6.13(1) of the Listing Rules of the UK Listing Authority:

 

Current and past directorships

Andrew Derodra

Skyepharma plc (current)

Tate & Lyle International Finance plc (past)

Frank Condella

Skyepharma plc (current)

Juniper Pharmaceuticals Inc. (current)

Thomas Werner

Skyepharma plc (current)

Basilea Pharmaceutica Ltd (current)

Medigene AG (past)

4SC AG (past)

 

No further information is required to be disclosed in respect of Andrew Derodra, Frank Condella or Thomas Werner under paragraph 9.6.13 of the Listing Rules of the UK Listing Authority.

-Ends-

 

Enquiries

 

Vectura Group plc

+44 (0)1249 667700

Karl Keegan, Chief Corporate Development Officer

 

 

 

Citigate Dewe Rogerson

+44 (0)20 7638 9571

David Dible / Mark Swallow

 

 

About Vectura

Vectura is a leading independent inhaled device, formulation, development and specialist commercial business focusing on the development of pharmaceutical therapies for the treatment of airways diseases. 

 

Vectura has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies.  Vectura currently has disclosed development collaborations and licence agreements with several global pharmaceutical and biotechnology companies, including Roxane Laboratories, Inc., Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.

 

Vectura develops products for airways diseases helping airways disease patients to improve their lives through uniquely applied insight and excellence in inhaled device engineering, formulation technology, product development and specialist commercialisation.

 

For further information, please visit Vectura's website at www.vectura.com.

 

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDNEAKDAALEKEFF

Quick facts: Vectura Group PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read